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Abstract
Chronic and acute graft-versus-host disease (cGVHD and
aGVHD) result from donor cells responding to host dispa-
rate MHC alleles. In cGVHD (H-2d -- H-2bd)), heightened
polyclonal immunoglobulin production is due to the interac-
tion of donor allospecffic helper T cells (Th) and the host B
cells. In vivo administration of antibody to the ligand for
CD40, gp39, blocked cGVHD-induced serum anti-DNA au-
toantibodies, IgE production, spontaneous immunoglobulin
production in vitro, and associated splenomegaly. Antibody
production remained inhibited for extended periods of time
after termination of anti-gp39 administration. Antialloge-
neic CTL responses induced in aGVHD were also prevented
by the in vivo administration of anti-gp39 as was the associ-
ated splenomegaly. These data suggest that CD40-gp39 in-
teractions are critical in GVHD and that CD40-gp39 may
be a valuable ligand-receptor pair for targeting immuno-
therapeutic agents to control GVHD. (J. Clin. Invest. 1994.
94:1333-1338.) Key words: CD40 * CD40 ligand - graft-
versus-host disease * T cells * B cells
Introduction
The chronic and acute forms of graft-versus-host disease
(GVHD)' (1) are characteristically associated with increased
polyclonal and autoimmune immunoglobulin (Ig) production
and increased allospecific cytotoxic T cell (CTL) activity, re-
spectively. In humans, GVHD occurs after bone marrow trans-
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1. Abbreviations used in this paper: aGVHD, acute graft-versus-host
disease; APC, antigen presenting cell; cGVHD, chronic graft-versus-
host disease; CTL, cytotoxic T cell; GVHD, graft-versus-host disease;
HIg, hamster immunoglobin; TD, thymus-dependent; Th, helper T cell.
plantation, and can be found in acute and chronic forms. Acute
GVHD (aGVHD) takes place within about 60 d post-trans-
plantation and results in damage to the skin, liver, and gut by
the action of cytolytic lymphocytes. Chronic GVHD (cGVHD)
occurs later and is a systemic autoimmune disease that affects
primarily the skin, resulting in the polyclonal activation of B
cells and the hyperproduction of Ig and autoantibodies (1).
GVHD is studied in experimental systems by the transfer
of parental lymphocytes into an F1 host (2, 3), resulting in the
donor cells responding to the host disparate MHC antigens (4-
6). In cGVHD, it has been shown that the heightened poly-
clonal Ig production is due to polyclonal B cell activation re-
sulting from cognate interactions between donor, allospecific
helper T cells (Th), and the host B cells (1, 4, 7). It has
previously been shown that the host B cells are responsible for
the autoantibody production due to excessive help provided by
donor-derived T cells (4, 5). Recently it has been shown that
normal host B cells, not the previously thought B 1 /CD5 + subset
of B cells, are responsible for this autoimmune phenomenon
(8, 9). The CD40 ligand, gp39, was recently cloned (10, 11)
and found to be a type II membrane protein expressed primarily
on activated CD4 + T cells (10- 13). It is known to be essential
in primary and secondary antigen-specific, syngeneic T-B
cognate interactions in vivo (14), and has been shown to be
an essential molecule in the development of collagen-induced
arthritis (15).
There is ample functional and genetic evidence that gp39
is essential for thymus-dependent (TD) immune responses (14,
16-19). gp39 is expressed transiently following the activation
of Th (20). During the course of TD immune responses in
vivo, gp39 is transiently expressed at high levels in defined
anatomical sites in the immune spleen on Th cells that are juxta-
posed to the responding B cells (21). These observations sup-
port the hypothesis that gp39-expressing Th delineate sites of
cognate Th-B cell interactions. Genetic proof that gp39-CD40
interactions are essential in the development of TD humoral
immunity is provided by the fact that defective expression of
the gp39 molecule is responsible for the development of X-
linked hyper-IgM syndrome (16-19). These patients have im-
paired TD immunity with low levels of IgG, IgA, and IgE, even
though their B cell responses to polyclonal activators in vitro
are normal. Taken together, these data conclusively demonstrate
that gp39-CD40 interactions are essential for TD B cell activa-
tion.
The role of CD40-gp39 interactions in the development of
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GVHD has not been studied. The data presented in this study
provide compelling evidence that gp39-CD40 interactions are
critical in the development of both cGVHD and aGVHD. Ad-
ministration of anti-gp39 prevented the onset of cGVHD as
judged by the reduction of hyperimmunoglobulin production,
splenomegaly, and anti-DNA antibodies, as well as the CTL
responses associated with aGVHD. Moreover, these studies pro-
vide the first in vivo evidence that anti-gp39 can impose pro-




DBA/2 (H-2d), C57BL/6 (H-2b) and B6D2F1 H-2b/d [(C57BL/6
x DBA/2) F1 hybrid] mice were obtained from the National Cancer
Institute laboratories (Bethesda, MD) and maintained in a viral-free
environment in the animal facility at Dartmouth Medical School. All
the mice used in this study were female, and aged 6 to 8 wks old.
Induction of chronic GVHD and acute GVHD
cGVHD was induced by the intravenous injection of parental (DBA/
2) spleen cells into nonirradiated (C57BL/6 x DBA/2) F1 hybrid
recipients (22). Parental mice were anesthetized and killed by cervical
dislocation prior to removal of the spleen. Dissociated spleen cells were
washed and resuspended in RPMI 1640 medium (Whittaker Bio-
products, Walkersville, MD) for intravenous injection (one spleen per
recipient) into the F. recipients. aGVHD was induced by the intravenous
injection of parental C57BL/6 spleen cells into nonirradiated (C57BL/
6 x DBA/2) F1 hybrid recipients. Cells were prepared for transfer as
for the induction of cGVHD.
Antibodies
Anti-gp39. MR1 was produced in ascites and purified by ion exchange
HPLC, as previously described (14, 23).
Polyclonal anti-isotype antibodies. All anti-IgG, and anti-IgA anti-
bodies and standard controls were obtained from Southern Biotechnol-
ogy Associates, Inc. (Birmingham, AL).
Anti-IgE antibodies. All anti-IgE antibodies (BIE3 and Biotin
EM95) and IgE standards (A3B1 ) were a kind gift from Dr. T. Waldsch-
midt, University of Iowa, (Iowa City, IA) and Daniel Conrad, Medical
College of Virginia (Richmond, VA).
Anti-MHC haplotype antibodies. Anti-H-2Kb (AF6-88.5) and anti-
H-2Dd (34-2-12) were obtained from PharMingen (San Diego, CA).
Cell lines
All tumor cell lines were obtained from the American Type Culture
Collection (Rockville, MD). These cells included P815 (H-2d, mouse
mastocytoma) c1 18.5 (H-2b, subclone of AKR H-2b-SLl; T cell
lymphoma), and LB27.4 (H-2bxd, Hybridoma; A20.2 fused to BIO.BR
spleen cells).
Polyclonal Ig production in vitro
Spleens from control and cGVHD mice were removed and single-cell
suspensions prepared. Cells were treated with Tris-buffered ammonium
chloride to remove erythrocytes and total white blood cell counts deter-
mined by visual hemocytometer counting. Cells were incubated (5
X 106) in 1 ml of complete (c)RPMI-1640 medium (Whittaker) [sup-
plemented with 10% FCS (Hyclone, Logan, UT), 25 mM Hepes, 2 mM
L-glutamine, 5,000 U/ml penicillin, and 5,000 U/ml streptomycin (all
from Sigma Diagnostics, St Louis, MO)] for 3 d at 37°C, 5% CO2.
Culture supernatants were collected by centrifugation to remove any
cells present. Ig was quantified by an isotype-specific ELISA assay.
Isotype-specific and antigen-specific ELISAs
ELISA for the detection of IgG, and IgA. 10 ,ug/ml goat anti-mouse
IgG, or IgA in PBS was absorbed onto wells of a 96-well polyvinyl
microtiter plate for 1 h at 370C, then overnight at 40C. Plates were
washed and blocked with PBS containing 1% FCS for 1 h at 370C.
Plates were washed again and the appropriate dilutions of supernatants
and standard controls, IgGI and IgA were added for 2 h at 370C. After
this time, the plates were washed three times and alkaline phosphatase-
conjugated goat anti-mouse IgGI or IgA (1/500 dilutions) was added
for 2 h at 370C. Plates were thoroughly washed and 1 j.g/ml phosphatase
substrate (Sigma Diagnostics) was added, resulting in the appropriate
color change. Readings were determined by an ELISA reader (Dynatech
Laboratories, Inc., Chantilly, VA) at an absorbence of 410 am. Concen-
trations of Ig were determined by comparison to the appropriate isotype
standard curve and expressed as the mean±SEM (n = 3).
ELISAfor the detection ofIgE. Wells of a 96-well polyvinyl microti-
ter plate were coated with an anti-mouse IgE capture antibody (B1E3
at 2 Htg/ml) overnight at 40C and then blocked with PBS containing
1% FCS for 1 h at 370C. Plates were washed again and the appropriate
dilutions of supernatants and standard controls (A3Bl [IgE]) were
added for 2 h at 370C. Plates were washed thoroughly and the EM95-
Biotin (5 Htg/ml) was added to each well and incubated for 2 h at 370C.
After this time alkaline phosphatase conjugated to streptavadin was
added (1/500 dilution) for a further 2 h. Plates then were developed,
as mentioned previously. Concentrations of Ig were determined by com-
parison to standard curve and expressed as the mean+SEM (n = 3).
ELISA for the detection ofanti-DNA antibodies. Calf thymus DNA
(Sigma Diagnostics) (5 jsg/ml) was dissolved in coupling buffer con-
taining 0.1 M sodium carbonate/sodium bicarbonate (pH 9.8). This
solution was boiled for 10 min and then incubated on ice for 3 min.
The OD260 of the DNA then was determined and the concentration was
adjusted to obtain the required 5 1g/ml DNA. 100 j1 then was added
to the wells of a 96-well polyvinyl microtiter plate and incubated over-
night at 4°C. The plate then was washed three times and blocked for 1
h at 37°C with PBS containing 1% FCS and 0.02% sodium azide. The
plate was washed again and serial dilutions of serum samples were
added (100 ,1, 1/500 final dilution) and incubated for 2 h at 370C. The
detection antibody, goat anti-mouse IgGI alkaline phosphatase, then
was added to each well and incubated once again for 2 h at 370C. Plates
were developed as mentioned previously. Antibody titers were compared
to a positive serum sample and results were expressed in arbitrary units.
Flow cytometric analysis for the detection of donor
derived cells
Spleens were removed from normal BDF1 and from cGVHD mice
treated with and without anti-gp39, and a single-cell suspension was
prepared. The cells were layered onto Ficoll-Hypaque (4:1 vol/vol) and
then centrifuged at 2,000 rpm for 20 min at room temperature. The
resulting lymphocyte layer was removed and washed once with buffered
saline solution containing 5% FCS. 106 cells per tube were used for
staining in a 50 jil final volume. 50 /61 of rat serum was added to each
tube to prevent nonspecific binding of antibodies. Cells were stained
with (a) the control antibodies: Rat Ig FITC (10lug/ml) and PE-Strep-
tavidin (2 ug/ml) and (b) FITC H-2Kb (10 Ag/ml) and Biotin H-2Dd
(10 /sg/ml). Cells were incubated for 20 min on ice and then washed
twice to remove any unbound antibodies. Finally PE-Streptavidin (2
Isg/ml) was added to the appropriate tube to detect the biotin-conjugated
antibody for another 20 min on ice. Cells were again washed twice ready
for analysis on a FACScan (Becton Dickinson Microbiology Systems,
Cockeysville, MD). After positive gating via forward and side scatter,
10,000 events were collected per sample for determination of percent
cells positive for the relevant MHC haplotype.
Assessment of CTL activity
Target tumor cell lines were labeled with the isotope by incubating 100
,ul of FCS containing 1-5 x 106 cells for 1 h at 370C with 0.2 mCi of
5"Cr (New England Biolabs, Beverly, MA). Cells then were washed
thoroughly and resuspended at 1 x i0' cells/ml in cRPMI. Labeled
targets were plated at 1 x 104 per well in 96 well plates with effector
cells in E/T ratios of 100:1, 20:1, and 4:1. Target cells used included
P815 (H-2d), LB27.4 (H-2bJd) and c118.5 (H-2b). The plates were
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Table I. Anti-gp39 Treatment Inhibits the Induction of cGVHD-
associated Splenonegaly and Spontaneous Antibody Production
In Vitro
Splenomegaly* Spontaneous in vitro ab
Fold increase in spleen production$
cell count of the
Group: control IgA IgG,
ng/ml ng/ml
Control 1 162±54 1±0.7
cGVHD 1.9±0.5 350±60 90±10
cGVHD + agp39 0.8±0.2 70±3 10±2
Chronic GVHD was induced by the intravenous injection of DBA/2 (H-
2d) spleen cells into nonirradiated (C57BL/6 x DBA/2) F, hybrid recipi-
ents. *At 14 d after cell transfer, spleens of host mice were removed
and cell counts were performed to determine the number of cells per
spleen. Those mice receiving anti-gp39 received 3 X 250 ig on days
0, 2, 4, and 6. Results are expressed as fold increase compared to the
control mice with means SEM±(n = 3). These results are representative
of three different experiments. *Spleens from mice with or without
cGVHD were cultured for 3 d in vitro and the levels of spontaneous
IgA and IgG, were determined by isotype-specific ELISAs. Results are
expressed as the mean concentration (ng/ml)±SEM (n = 3). These
results are representative of three different experiments.
briefly centrifuged and then incubated at 370C in 5% CO2 for 4 h. The
plates were centrifuged once more, and an aliquot of cell-free superna-
tant was collected from each well for counting by a gamma counter
(model LKB 1272; Clinigamma, Wallac Inc., Gaithersburg, MD). Per-
cent-specific lysis is defined as (a - b)/c where a equals cpm released
by target cells incubated with effector cells, b equals cpm released by
target cells incubated with media only (spontaneous release), and c
equals freeze-thaw releasable cpm from target cells (- 80% of total
cpm incorporated).
Results
Anti-gp39 inhibits GVHD-induced splenomegaly and hyper Ig
production. In cGVHD, it is primarily the host's own cells that
infiltrate and enlarge the spleen, although this is in response
to the presence of donor cells (5). In the mouse, one of the
consequences of this condition is the enlargement of the spleen.
Table I indicates that at 14 d after the initiation of cGVHD,
spleens contain almost twice the number of leukocytes com-
pared to mice without cGVHD. Treatment of mice at the onset
of cGVHD with anti-gp39 (250 jug/mouse, days 0, 2, 4, and
6) reduced the number of leukocytes per spleen in cGVHD
mice to levels that were indistinguishable from mice without
disease. It has been reported that hyperproduction of Ig occurs
in mice with cGVHD due to cognate interactions between donor
T cells and host B cells (4, 8, 24). To determine whether anti-
gp39 inhibits hyper-Ig production 14 d after the initiation of
disease, spleens were removed from control and cGVHD mice
and the B cells assayed for the spontaneous production of IgG,
and IgA in vitro. Splenocytes from mice with cGVHD produced
high levels of IgA and IgG, in vitro (Table I). However, spleno-
cytes from mice treated with anti-gp39 (days 0, 2, 4, and 6)
produced levels of IgG, and IgA similar to mice without disease.
The addition of anti-gp39 to cultures of spleen cells from mice
with cGVHD did not reduce the levels of in vitro Ig production,
suggesting that anti-gp39 was exerting its effects in vivo (data
not shown).
In all initial studies, purified hamster Ig (HIg) was used as
a control for treatment with the hamster monoclonal anti-gp39
(data not shown). When HIg was used as a control for these
experiments, it showed no inhibitory effect on the induction of
cGVHD, but actually enhanced the cGVHD in terms of poly-
clonal Ig production and the resultant splenomegaly. A two- to
fourfold increase in in vitro Ig production was detected in the
level of Ig produced in cGVHD mice given HIg over that ob-
served in cGVHD mice not given antibodies (data not shown).
Consequently it was decided to designate the untreated (receiv-
ing no antibodies) F, recipient mice as the relevant control
group so as not to bias the data due to the enhanced response
obtained with HIg.
Anti-gp39 inhibits cGVHD-induced hyper-IgE and anti-
DNA autoantibodies. The course of cGVHD can be monitored
by the elevation in serum IgE and antibodies to double-stranded
DNA (1). Levels of serum IgE were measured using an IgE-
specific ELISA. cGVHD-induced mice were treated with anti-
gp39 on days 0, 2, 4 and 6, and then no further antibody was
administered. Mice were bled at regular intervals and the levels
of serum IgE ascertained (Fig. 1 A). cGVHD induced a 10-
15-fold increase in serum IgE levels. Administration of anti-
gp39 for the first 6 d inhibited cGVHD-induced increases in
serum IgE throughout the 8-wk time frame of the experiment.
In addition to the inhibition of elevated serum IgE, administra-
tion of anti-gp39 also blocked the generation of serum anti-
DNA autoantibodies. Increases of 5-10-fold in the levels of
anti-DNA antibodies were found in cGVHD (Fig. 1 B).
Anti-gp39 does not alter the frequency of engrafted, donor-
derived cells in cGVHD mice. Because the effects of anti-gp39
treatment were apparent for long periods of time (> 8 wks), it
was important to assess whether anti-gp39 treatment altered the
presence of donor cells in recipient mice during the initial stages
of disease induction. Spleens from cGVHD-induced mice had
- 5-7% single positive (H-2d) donor-derived cells (Fig. 2)
after 7 d of disease progression. The administration of anti-
gp39 to cGVHD mice did not alter the frequency of donor-
derived cells found in the host.
Effect of anti-gp39 treatment on the induction of aGVHD.
aGVHD is associated with the induction of a profound antiallo-
geneic CTL response. While it is clear that gp39-CD40 interac-
tions are critical for Th-B cell interactions, it is not clear if the
development of cell-mediated immunity may also be altered by
anti-gp39 therapy. aGVHD was induced by the administration
of C57BL/6 spleens to the F, recipients. As shown in Fig. 3,
12 d following the transfer of donor cells, a robust H-2b anti-
H-2d CTL response was measured. Treatment of mice with
anti-gp39, but not HIg, prevented the generation of H-2b-de-
rived CTL against H-2 . Controls in this experiment included
mice receiving parental cells with no antibody or HIg. The
CTL responses of mice receiving no antibody and HIg were
indistinguishable.
Discussion
The present study demonstrates that the in vivo administration
of anti-gp39 blocks the following GVHD-associated phenom-
ena: splenomegaly, in vitro polyclonal Ig production, elevated
levels of serum IgE and anti-DNA antibodies, and the genera-
tion of anti-host cytotoxic T cells. The long term prevention














Figure 1. Anti-gp39 treatment inhibits the induction of serumIgE and
anti-DNA autoantibody production associated with cGVHD. Levels of
(A)IgE and (B) anti-DNA autoantibody from serum of animals induced
with cGVHD either untreated (m) or treated with anti-gp39 (e) were
determined by ELISA. All results are compared to IgE standards and
expressed in ng/ml±SEM (n = 3) forIgE serum levels, and for anti-
DNA antibodies compared to a positive serum, and thus expressed in
arbitrary units±SEM (n = 3).
of GVHD was induced by a brief treatment with anti-gp39,
suggesting that permanent alterations in host allospecific re-
sponses were imposed by blocking gp39-CD40 interactions.
Based on data reported in this paper and with the work of
others (1, 4, 7), it appears that hyper Ig production, elevated
levels of serumIgE, and titers of serum anti-DNA antibodies are
induced through a cognate, gp39-CD40-dependent interaction.
Published studies have established that host B cells are responsi-
ble for autoantibody production (4, 5, 8) in cGVHD. Therefore,
expression of gp39 on the donor T cells is likely to be responsi-
ble for the heightened levels ofIg. These observations are in
accord with other studies (1, 4, 7) indicating that cognate inter-
actions, and not lymphokines, are responsible for the activation
of host B cells by allogeneic T cells.
Detection of donor-derived cells in anti-gp39 treated and
untreated mice with cGVHD indicates that the allogeneic cells
are present but unable to respond. The existence of donor cells
has been shown previously up to 10 wks after induction of
cGVHD (25). The prolonged negative effect that anti-gp39
imposed on cGVHD was different from its observed effect on
syngeneic, antigen-specific humoral immune responses (14).
Administration (days 0, 2, and 4) of anti-gp39 inhibited antigen-
specific, humoral immune responses for periods up to 3-4 wks,
with a return to normal responsiveness at the end of that time
interval. Based on a number of factors, the inhibition of antigen-
specific immune responses in vivo by anti-gp39 indicated that
anti-gp39 mediated its effects by the simple blockade of gp39-
CD40 interactions and when the antibodies were cleared, im-
mune responses returned (14). By contrast, in cGVHD, preven-
tion of hyper-IgE and elevated titers of anti-DNA antibodies
persisted for at least 8 wks after the termination of anti-gp39
therapy, and none of the mice were observed to relapse with
disease (data not shown). These results indicate that allospecific
T cell activities are affected either by clonal deletion or anergy
of the alloreactive T cells. The induction of allospecific T cell
unresponsiveness induced by anti-gp39 is also indicated in
aGVHD. High levels of allospecific CTL activity were mea-
sured in mice with aGVHD. However, when anti-gp39 was
administered at the onset of disease, no anti-host CTL activity
was identified.
There are a number of possible mechanisms through which
anti-gp39 may have blocked the development of both forms of
GVHD. It is unlikely that anti-gp39 blocked T cell respon-
siveness by a direct cytotoxic effect on T cells because it has
been shown that anti-gp39 (MR1 mAb) does not physically
delete gp39-bearing T cells in vivo (21). One hypothesis is
that the blockade of CD40 signaling by anti-gp39 prevented
expression of costimulatory molecules that are required for allo-
antigen presentation. The most extensively described receptor
system that is involved in such costimulation is CD28/CTLA-
4 receptor, with its B7.1/B7.2 coreceptor (26-29) (reviewed
in 30). Upregulation of B7.1 can be mediated through CD40
signaling as has been shown by Ranheim et al. (31) on normal
and leukemic B cells. Therefore, it can be suggested that during
cognate interactions between allogeneic donor T cells and host
B cells, blockade of gp39 signaling prevented the upregulation
of costimulatory molecules (i.e., B7.1/B7.2) on the host B
cells. As a consequence, the alloreactive CD4+ Th cells were
deprived of the required costimulatory signals and rendered
unresponsive. The requirement for costimulatory molecules in
the activation of alloreactive CD4+ has been repeatedly demon-
strated in studies employing CTLA-4-Ig and anti-B7 antibodies
(28, 32). Since Th cells and their products (lymphokines) have
been shown to be important in the development of CD4-depen-
dent CTL (33-35), induction of tolerance in the CD4 compart-
ment would impair the development of CTL. Perhaps an even
more critical factor is that the lack of enhanced costimulatory
molecule expression on class I MHC-bearing antigen presenting
cells (APC) directly prevented the activation of alloreactive
CTL. Therefore, CTL development may have been prevented
because of both a lack of T cell help and the inability of APC
to effectively activate alloreactive CD8+ T cells.
This hypothesis does not contend that B cells were the pre-
eminent cell for the induction of antiallogeneic responses in
GVHD, but suggests that if B cells were prevented from becom-
ing activated, they tolerized the transferred donor cells before
those donor T cells were activated by host, professional APC.
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Figure 2. Identification of donor-derived
cells within the recipient splenic cell popula-
tion. Donor-derived cells (DBA/2, H-2') . *;
were identified within the recipient spleen .10
cells (BDFl, H-2db) by two-color flow cy-
tometry. Recipient cells stain positively for.
both H-2Kb and H-2Dd antibodies, whereas
DBA/2-derived cells only stain H-2Dd posi-
tively.
This is reasonable given the large number of quiescent B cells
that could putatively act as vehicles of tolerance induction com-
pared to the more limited number of professional APC. In addi-
tion to B cells, both activated monocytes and dendritic cells
express CD40, and it may be that CD40-triggering influenced
the ability of these APC to present antigen. Therefore, the cur-
rent hypothesis contends that there is a CD40-dependent trig-
gering that is essential for some unidentified APC (perhaps B
cells) to elicit a positive allogeneic T cell response.
Alternative interpretations of the data presented are also
possible. Since T cell receptor signaling, via anti-CD3, of T
cells can be augmented by recombinant gp39 (36), it could be
argued that anti-gp39 is blocking T-T cell signaling and
blocking a critical costimulatory effect required for the genera-
Figure 3. Anti-gp39 inhibits so
CTL formation associated
with aGVHD induction. 4"
CTL formation was deter- m 30-
mined for spleens derived \20
from naive BDFI animals 5 0
(m), and BDF, animals in- W 10-
duced with aGVHD and ei- a
ther untreated (A), treated 0
with HIg (c), or adminis- -so
tered anti-gp39 (*). Data 100:1 20:1 4:1
represents responses derived
using P815 (H-2d) cells as E:T Ratio
targets. When LB27.4
(H-2 bxd) targets were used, percent specific lysis was approximately
half of that obtained for P815 at all E/T ratios (data not shown)
and no CTL activity was obtained using the cl 18.5












tion of CTL. Each of these possible mechanisms is under study
to resolve which is operative in the system that has been pre-
sented. Irrespective of the mechanisms involved in disease pre-
vention by anti-gp39, anti-gp39 therapy in humans may provide
a novel strategy to prevent GVHD.
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